HE006

Main objectives 1. To evaluate the safety and tolerability of HE006 tablets in patients with relapsed/refractory acute myeloid leukemia; 2. To determine the maximum tolerated dose (MTD) or maximum escalation dose (MAD) of HE006 tablets, as well as the recommended dose for phase II (RP2D). Secondary objectives 1. To evaluate the pharmacokinetic (PK) characteristics of HE006 tablets after single and multiple oral administration in patients with relapsed/refractory acute myeloid leukemia; 2. To evaluate the clinical effectiveness of HE006 tablets in patients with relapsed/refractory acute myeloid leukemia. Other objectives 1. To evaluate the changes in pharmacodynamic (PD) indicators of HE006 tablets in patients with relapsed/refractory acute myeloid leukemia; 2. To evaluate the relationship between exposure, efficacy and adverse events (AEs) of HE006 tablets in patients with relapsed/refractory acute myeloid leukemia (if data permit); 3. To identify plasma metabolites of HE006 tablets in patients with relapsed/refractory acute myeloid leukemia (if applicable).